4502 On Other Exchanges
4502 is not on other exchanges.

takeda pharmaceutical co ltd (4502) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TAKEDA PHARMACEUTICAL CO LTD (4502)

Related News

No related news articles were found.

takeda pharmaceutical co ltd (4502) Details

Takeda Pharmaceutical Company Limited engages in the research and development, manufacture, marketing, and sale of pharmaceutical products worldwide. The company operates through three segments: Ethical Drugs, Consumer Healthcare, and Other. It provides products in various therapeutic areas, including gastroenterology, oncology, central nervous system, cardiovascular and metabolic, vaccines, and others. The company has an agreement with Altos Therapeutics LLC for the development of ATC-1906 compound as an oral dopamine D2/D3 receptor antagonist that addresses the symptoms of nausea and vomiting in GP patients; and a research collaboration with Affilogic to explore Nanofitins platform in therapies targeting the central nervous system. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Osaka, Japan.

Founded in 1781

takeda pharmaceutical co ltd (4502) Top Compensated Officers

Chief Executive Officer, President and Repres...
Total Annual Compensation: ¥230.0M
Corporate Strategy Officer and Director
Total Annual Compensation: ¥85.0M
Compensation as of Fiscal Year 2015.

takeda pharmaceutical co ltd (4502) Key Developments

Takeda Pharmaceutical Company Limited Announces Two Interim Reports from the Ongoing, Open-Label GEMINI Long-Term Safety Study

Takeda Pharmaceutical Company Limited announced that two interim reports from the ongoing, open-label GEMINI long-term safety (LTS) study describing clinical data of long-term Entyvio (vedolizumab) treatment in patients with moderately to severely active ulcerative colitis (UC) and moderately to severely active Crohn's disease (CD). The data showed that patients with moderately to severely active UC experienced clinical and health-related quality of life (HRQL) improvements with continued vedolizumab treatment. For patients with moderately to severely active CD, the clinical benefits of vedolizumab continued with long-term treatment regardless of prior TNF antagonist exposure. UC and CD patients that entered the study after discontinuing prior eight-weekly maintenance dosing due to loss of clinical response, in GEMINI I and II respectively, could experience a beneficial effect with increasing dosing frequency to every four weeks.

Takeda Pharmaceutical Company Limited Enters into Research Collaboration with Affilogic

Takeda Pharmaceutical Company Limited announced that it has entered into a research collaboration with Affilogic. The collaboration would explore using Affilogic's proprietary Nanofitins platform in therapies targeting the central nervous system. Under the terms of the agreement, Affilogic will receive an upfront payment and research funding, and is eligible to receive additional development and sales milestone payments and royalties by Takeda. Takeda will be entitled to commercialize worldwide products incorporating Affilogic Nanofitins resulting from the collaboration. Further details of the agreement were not disclosed. Specifically, Affilogic and Takeda, through its research center in San Diego, California, will leverage their respective competencies to validate and optimize Nanofitins that enable Takeda to deliver biotherapeutic candidates into the brain to address neurological disorders.

Takeda Pharmaceutical Company Limited Receives Positive CHMP Opinion for Conditional Approval of Ninlaro (Ixazomib)

Takeda Pharmaceutical Company Limited announced that the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the conditional approval of NINLARO™ (ixazomib) capsules in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. If the European Commission ratifies the CHMPs opinion and authorization is granted, NINLARO will be the first and only oral proteasome inhibitor approved for use across the European Economic Area, which includes the 28 member states of the European Union as well as Norway, Liechtenstein and Iceland. The improvement in progression free survival in this difficult-to-treat stage of myeloma is significant. In addition to ixazomibs efficacy in this relapsed and/or refractory group of patients, its manageable safety profile and oral administration makes ixazomib a very welcome new treatment option for this serious and complex cancer. It is important that attention is now turned in earnest to the Health Technology Assessment bodies to ensure their approval of ixazomib. Data from the pivotal Phase 3 trial TOURMALINE-MM1 demonstrate that the addition of NINLARO to lenalidomide and dexamethasone provides a significant improvement in progression-free survival when compared to placebo plus lenalidomide and dexamethasone in this patient population. Patients continue to be treated to progression in the trial, with additional evaluations planned for long-term outcomes such as overall survival. The heterogeneity of multiple myeloma means that it is very important for patients and physicians to have access to a variety of treatment options, and many physicians are now looking forward to the possibility of adding NINLARO to treatment armamentarium, said Philippe Moreau, MD, Head of the Hematology Department at the University Hospital of Nantes, France. The clinical data strongly support the use of NINLARO in relapsed and/or refractory patients, while also delivering the advantages of an all-oral triplet regimen. In the TOURMALINE-MM1 trial, the NINLARO regimen showed a significant improvement in progression-free survival of 35% when compared to the placebo regimen. Currently approved proteasome inhibitors are only available through twice-weekly injections and infusions, which can place additional logistical burdens on patients and their caregivers, who already are dealing with a difficult disease.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4502 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4502.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4502 Industry Range
Price/Earnings 24.2x
Price/Sales 2.1x
Price/Book 2.1x
Price/Cash Flow 14.0x
TEV/Sales 1.2x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact TAKEDA PHARMACEUTICAL CO LTD, please visit www.takeda.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.